Home > Insider Trading > Filing (0001104659-23-071204)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1829635	Transcode Therapeutics Inc.	RNAZ	Pharmaceutical Preparations (2834)	811065054

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1854161	Michael Robert Dudley	C/O Transcode Therapeutics, Inc. 6 Liberty Square, #2382 Boston MA 02109	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-06-09	19,000	$2.76	61,155	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Footnotes

Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.675 to $2.85. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.
This Form 4/A amends the Form 4 originally filed on June 13, 2023 solely to correct the amount reported in Table I, Column 5. Due to an administrative error, the amount reported on the original Form 4 was not adjusted to reflect a 1-for-20 reverse stock split of the Company's common stock, which became effective as of May 22, 2023.